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David S. Shames, Dustin Smith, Wei Yu, Virginia E. Paton, and Tony Mok
A B S T R A C T
Purpose
The phase III OAM4971g study (METLung) examined the efﬁcacy and safety of onartuzumab plus
erlotinib in patients with locally advanced or metastatic non–small-cell lung cancer selected by MET
immunohistochemistry whose disease had progressed after treatment with a platinum-based
chemotherapy regimen.
Patients and Methods
Patients were randomly assigned at a one-to-one ratio to receive onartuzumab (15 mg/kg in-
travenously on day 1 of each 21-day cycle) plus daily oral erlotinib 150mg or intravenous placebo plus
daily oral erlotinib 150 mg. The primary end point was overall survival (OS) in the intent-to-treat
population. Secondary end points included median progression-free survival, overall response rate,
biomarker analysis, and safety.
Results
A total of 499 patients were enrolled (onartuzumab, n = 250; placebo, n = 249). Median OS was 6.8
versus 9.1months for onartuzumab versus placebo (stratiﬁed hazard ratio [HR], 1.27; 95%CI, 0.98 to
1.65; P = .067), with a greater number of deaths in the onartuzumab arm (130 [52%] v 114 [46%]).
Median progression-free survival was 2.7 versus 2.6 months (stratiﬁed HR, 0.99; 95% CI, 0.81 to
1.20; P = .92), and overall response rate was 8.4% and 9.6% for onartuzumab versus placebo,
respectively. Exploratory analyses using MET ﬂuorescence in situ hybridization status and gene
expression showed no beneﬁt for onartuzumab; patients with EGFR mutations showed a trend
toward shorter OS with onartuzumab treatment (HR, 4.68; 95% CI, 0.97 to 22.63). Grade 3 to 5
adverse events were reported by 56.0% and 51.2% of patients, with serious AEs in 33.9% and
30.7%, for experimental versus control arms, respectively.
Conclusion
Onartuzumab plus erlotinib did not improve clinical outcomes, with shorter OS in the onartuzumab
arm, compared with erlotinib in patients with MET-positive non–small-cell lung cancer.
J Clin Oncol 35:412-420. © 2016 by American Society of Clinical Oncology
INTRODUCTION
MET is a transmembrane receptor tyrosine kinase
activated by hepatocyte growth factor (HGF) and
plays a role in embryonic development and
wound healing.1,2 Aberrant MET signaling can be
driven by autocrine production of HGF, over-
expression of MET, and ampliﬁcation of theMET
gene and may be an oncogenic factor in several
human malignancies.3-6 Overexpression of MET
is associated with poor prognosis in non–small-
cell lung cancer (NSCLC); high MET gene copy
number is linked with reduced overall survival
(OS; hazard ratio [HR], 1.877; P = .0414) and an
increased risk of death after resection (HR, 1.618;
P = .024).7,8
Unselected patients with recurrent NSCLC
are often treated with the epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor (TKI)
erlotinib, which improves patient outcomes in
second-line therapy9 and in ﬁrst-line treatment
for EGFR mutation–positive NSCLC.10-13 How-
ever, resistance to EGFR inhibitors frequently de-
velops. MET and EGFR are often coexpressed, and
MET can upregulate EGFR ligand expression, pos-
sibly providing a mechanism for the development of
erlotinib resistance. Furthermore, ampliﬁcation of
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the MET gene occurs in lung cancers with acquired resistance to
EGFR TKIs, demonstrating the synergy between MET and EGFR
signaling.14,15
Onartuzumab is a recombinant, fully humanized, monovalent
monoclonal antibody that binds the extracellular domain of MET,
blocking interaction with HGF. This prevents activation of the
METsignaling pathway, inhibiting the downstream events that lead
to tumorigenesis.16 Onartuzumab was designed as a monovalent
antibody because bivalent antibodies mimic HGF, stimulating
MET signaling, whereas monovalent antibodies act as antago-
nists.16 Results from a phase II study of onartuzumab plus erlotinib
in patients with NSCLC suggested that in patients with MET-
positive disease, progression-free survival (PFS) and OS were
improved compared with placebo plus erlotinib17 and that these
results warranted further investigation. Here we report the efﬁcacy
and safety results of the phase III METLung trial (OAM4971g)
comparing onartuzumab plus erlotinib with placebo plus erlotinib
for patients with MET-positive NSCLC after platinum-based
chemotherapy.
PATIENTS AND METHODS
Study Design
OAM4971g (METLung) was a randomized, multicenter, double-
blind, placebo-controlled phase III trial evaluating the efﬁcacy and
safety of onartuzumab plus erlotinib in patients with locally advanced or
metastatic NSCLC whose disease had progressed after prior chemotherapy.
Patients were randomly assigned at a one-to-one ratio to receive either
onartuzumab (15 mg/kg intravenously [IV] on day 1 of each 21-day cycle)
plus daily oral erlotinib 150 mg or IV placebo plus daily oral erlotinib
150 mg. Patients were randomly assigned using a permuted-block method
to ensure approximately equal numbers in the two treatment arms and
were stratiﬁed by MET immunohistochemistry (IHC) clinical score (2+ v
3+), number of prior lines of therapy (one v two), histology (nonsquamous
v squamous), and EGFR mutation status (activating mutation v wild type
[by cobas EGFR assay; Roche Molecular Diagnostics, Pleasanton, CA]).
Patients received treatment until disease progression (PD), unacceptable
toxicity, patient or physician decision, or death. The study was conducted
in accordance with the principles of the Declaration of Helsinki and Good
Clinical Practice. All patients provided written informed consent before
any study-related procedures.
Patients
Patients with stage IIIB to IV locally advanced or metastatic NSCLC
determined to be MET positive ($ 50% of tumor cells with IHC scores of
2+ [moderate] or 3+ [strong] levels of MET5) were enrolled. Patients had
developed PD after one previous line of platinum-based chemotherapy but
had not received more than two prior lines of treatment and had Eastern
Cooperative Oncology Group performance status of 0 or 1.
Key exclusion criteria included prior treatment with an EGFR in-
hibitor, untreated brain metastases, interstitial lung disease, pleural ef-
fusion, pericardial ﬂuid or ascites, serious active infection, uncontrolled GI
inﬂammatory disease, uncontrolled diabetes mellitus, major surgery
2 weeks before random assignment, and history of other invasive ma-
lignancy or cardiac disease.
Study End Points
The primary end point was OS in the intent-to-treat (ITT) pop-
ulation. Secondary end points included PFS and overall response rate
(ORR) in the ITT population, biomarker analysis, and safety in the safety
population.
Assessments
Tumor response was evaluated every 6 weeks until PD or death using
RECIST (version 1.1). OSwas calculated from the date of random assignment
until death resulting from any cause. Repeat chest and abdominal computed
tomography or magnetic resonance imaging scans were performed by the
investigator every 6 weeks (6 7 days; before the start of every odd-numbered
cycle) for the ﬁrst 12 months and then every 12 weeks (6 14 days) thereafter.
PFS was calculated from the date of random assignment until the date
of ﬁrst PD or death, whichever occurred ﬁrst. ORR was deﬁned as the
percentage of patients with measurable disease at baseline whose tumors
had a complete (CR) or partial response.
Adverse events (AEs) were recorded and graded according to the
National Cancer Institute CommonTerminologyCriteria for AEs (version 4.0)
and classiﬁed according to the Medical Dictionary for Regulatory Activities.
Patients were observed until death or discontinuation of trial participation.
MET and EGFR Status
The provision of tumor samples (archival tissue block or 15 serial cut
unstained slides) was mandatory. Tumor samples were tested centrally
(LabCorp, Burlington, NC; Histogenix, Antwerp, Belgium) to determine
METexpression status (using the Ventana [Tucson, AZ] anti-Total c-MET
[SP44] rabbit monoclonal antibody IHC assay) and EGFR status (cobas
EGFR assay; Roche Molecular Diagnostics). A patient’s disease was con-
sidered positive if his or her tumor sample demonstrated at least 50% of
cells stained positive with an intensity of 2+ or greater per Ventana
investigational-use-only assay system guidelines.
Exploratory biomarkers were assessed in formalin-ﬁxed parafﬁn-
embedded tumor samples obtained from patients at enrollment. Samples
were used for ﬂuorescence in situ hybridization (FISH) analysis using
a CEP7 centromere probe (Abbott Molecular, Abbott Park, IL), and
a cutoff of ﬁve or more copies of MET per cell was predeﬁned as the
criterion for FISH-positive status.5,18,19 The link between MET ampliﬁ-
cation and MET-positive status by IHC was assessed, as was the impact of
FISH status on OS, PFS, and ORR. The inﬂuence of EGFRmutation status
on OS and PFS was investigated, and OS, PFS, and ORR were assessed in
patients with ampliﬁed gene expression. Further mutation analysis was
performed using a multiplex ﬂuidigm platform.20
Statistical Analysis
The trial was designed to enroll approximately 490 patients. Final
analysis was planned at 364 OS events, with one interim analysis planned
after 67% of OS events. The interim analysis rejection boundaries were
calculated to be HR of 0.73 or less (one-sided P # .006) for superior
efﬁcacy and HR of 0.94 or greater (one-sided P $ .32) for futility.
The ITT population included all randomly assigned patients, grouped
according to treatment assigned at random allocation regardless of whether
they received any study treatment. The safety population included all
randomly assigned patients who received at least one dose of study
treatment, grouped according to whether any full or partial dose of
onartuzumab or placebo was received.
Median PFS andmedianOSwere estimated using Kaplan-Meier analysis.
Estimated HRs and 95% CIs of PFS and OSwere determined using a stratiﬁed
Cox regression model. Estimates of ORRs and 95% CIs were calculated using
the Blyth-Still-Casella method. ORRs in the treatment groups were compared
using the stratiﬁed Mantel-Haenszel test, and 95% CIs were determined using
the normal approximation to the binomial distributions. Biomarker subgroup
analyses for OS, PFS, and ORR were performed using formalin-ﬁxed parafﬁn-
embedded tumor samples obtained from patients at enrollment.
RESULTS
Patients
Between January 2012 and August 2013, 499 patients were
randomly assigned to receive onartuzumab plus erlotinib (n = 250)
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or placebo plus erlotinib (n = 249). Of the 499 patients enrolled,
seven (two [0.8%] in the onartuzumab arm and ﬁve [2.0%] in the
placebo arm) did not receive any treatment (Fig 1). At primary data
cutoff (October 26, 2013) for the planned interim analysis,
23 patients (9.2%) in the onartuzumab arm and 29 (11.6%) in the
placebo arm were still receiving onartuzumab or placebo. Patient
characteristics were generally well balanced between the two
treatment arms (Table 1). Median patient age was 61.5 years (range,
24 to 84 years), and 55.7% were men. Most patients (78.8%) had an
MET IHC score of 2+, and 88.6% had no activating EGFRmutation.
Efficacy
After the required number of OS events (244), the interim
analysis was performed. Median duration of follow-up was
7.6 months in the onartuzumab arm and 8.0 months in the placebo
arm. Analysis of the primary end point showed the number of
deaths was greater in the onartuzumab arm than in the placebo
arm (130 [52%] v 114 [46%], respectively; Fig 2A). Median OS was
6.8 months in the onartuzumab arm versus 9.1 months in the
placebo arm. The stratiﬁed HR was 1.27 (95% CI, 0.98 to 1.65; log-
rank P = .067). Analysis of OS in key clinical subgroups of the ITT
population showed that results were consistent with the overall ITT
population (Fig 2B).
PFS analysis in the ITT population showed that there were
more events in the onartuzumab arm (210 [84%]) than in the
placebo arm (204 [82%]; Fig 3A). Median PFS was similar between
arms (2.7 v 2.6 months in the onartuzumab v placebo arm, re-
spectively), and the stratiﬁed HR was 0.99 (95% CI, 0.81 to 1.20;
log-rank P = .92). Findings from an analysis of PFS in key clinical
subgroups were consistent with the overall ITT population results
(Fig 3B).
The ORR was similar between the two arms: 8.4% in the
onartuzumab arm compared with 9.6% in the placebo arm. One
Randomly assigned
(N = 499)
Onartuzumab plus erlotinib
(n = 250)
Placebo plus erlotinib
(n = 249)
Did not receive treatment
(n = 2)
Did not receive treatment
(n = 5)
Received treatment
(n = 248)
Received treatment
(n = 244)
Early discontinuation
   Disease progression
   Adverse event
   Died
   Withdrawal of patient consent
   Physician decision
   Lost to follow-up
   Other
(n = 225; 90.0%)
   (n = 170; 68.0%)
(n = 20; 8.0%)
 (n = 20; 8.0%)
 (n = 8; 3.2%)
(n = 5; 2.0%)
(n = 1; 0.4%)
 (n = 1; 0.4%)
Early discontinuation
   Disease progression
   Adverse event
   Died
   Withdrawal of patient consent
   Physician decision
   Other
(n = 215; 86.3%)
 (n = 167; 67.1%)
(n = 11; 4.4%)
(n = 15; 6.0%)
(n = 11; 4.4%)
(n = 10; 4.0%)
(n = 1; 0.4%)
Screened
(N = 1,790)
Fig 1. CONSORT diagram of patient ﬂow through the study. Primary efﬁcacy analysis cutoff: October 26, 2013.
Table 1. Baseline Characteristics of the ITT Population
Characteristic
No. (%)
Onartuzumab + Erlotinib
(n = 250)
Placebo + Erlotinib
(n = 249)
Median age, years 62 63
Sex
Male 139 (56) 139 (56)
Female 111 (44) 110 (44)
ECOG PS
0 93 (37) 78 (31)
1 153 (61) 169 (68)
2 4 (2) 1 (0.5)
Missing 0 (0) 1 (0.5)
Asian race 35 (14) 37 (15)
Histology*
Nonsquamous 210 (84) 218 (88)
Squamous 40 (16) 31 (12)
Prior lines of therapy*
Two 161 (64) 157 (63)
Three 89 (36) 92 (37)
EGFR mutation positive* 28 (11.2) 29 (11.6)
MET IHC*
2+ 198 (79) 195 (78)
3+ 52 (21) 54 (22)
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance
status; IHC, immunohistochemistry; ITT, intent to treat.
*Stratiﬁcation factor
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1.0
0.8
0.6
0.4
0.2
Onartuzumab + erlotinib 250 177 100 29 12 4
Placebo + erlotinib 249 183 110 43 14 3 1
No. of patients at risk
Onartuzumab + erlotinib: HR, 1.27; 95% CI, 0.98 to 1.65
Time Since Treatment (months)
OS
 (p
ro
ba
bi
lit
y)
0 3 6 9 12 15 18 21
Placebo + erlotinib (n = 249)
Onartuzumab + erlotinib (n = 250)
A
Baseline Risk Factors
Total
No.
Median
(months)
Placebo + Erlotinib
(n = 249)
Events
Sex
Age group, years
ECOG PS
MET IHC score
Prior lines of therapy
Histology
EGFR mutation
Median
(months)
Onartuzumab + Erlotinib
(n = 250)
EventsNo. 95% CIHRNo.
All patients 499 249 114 9.1 250 130 0.98 to 1.631.27
Male 278 139 71 7.0 139 79 0.85 to 1.621.17
Female 221 110 43 9.9 111 51 0.90 to 2.051.36
< 65 295 143 72 9.1 152 84 0.91 to 1.711.25
65–75 167 90 36 9.4 77 37 0.74 to 1.861.17
> 75 37 16 6 14.7 21 9 1.06 to 13.843.83
Race 
Asian 72 37 13 10.2 35 9 0.30 to 1.670.71
Black or African American 12 8 3 NE 4 2 0.32 to 16.232.26
Native Hawaiian or other Pacific Islander 1 1 0 NE to NENE
White 362 180 85 9.0 182 103 0.98 to 1.741.30
Multiple 34 16 9 9.6 18 8 0.53 to 3.711.41
Other race 4 1 0 NE 3 2 0.00 to NE> 999.99
Unknown 14 7 4 7.4 7 6 0.26 to 3.620.86
0 171 78 27 10.2 93 34 0.73 to 2.011.21
1 or 2 327 170 87 7.0 157 96 0.99 to 1.771.32
2+ 393 195 86 9.4 198 105 1.02 to 1.801.35
3+ 106 54 28 9.1 52 25 0.59 to 1.751.02
1 318 157 72 9.0 161 79 0.82 to 1.551.13
2 181 92 42 9.4 89 51 1.07 to 2.451.62
Nonsquamous 428 218 95 9.8 210 109 1.02 to 1.771.34
Squamous 71 31 19 6.4 40 21 0.47 to 1.640.88
Yes 57 29 2 NE 28 7 0.97 to 22.634.68
No 442 220 112 7.8 222 123 0.92 to 1.54
6.8
6.4
8.8
6.5
7.5
7.6
NE
5.0
NE
6.4
6.5
4.2
4.9
9.0
5.9
6.8
6.4
7.1
6.3
6.5
7.2
12.6
6.4 1.19
1/100
Favors
onartuzumab +
erlotinib
Favors
placebo +
erlotinib
1 100
B
Fig 2. (A) Kaplan-Meier curves of overall survival (OS) in the intent-to-treat population. Crosses indicate censored patients. (B) Subanalysis of OS in key clinical subgroups.
ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; IHC, immunohistochemistry; NE, not evaluable.
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patient (0.4%) in the placebo arm had a CR, whereas no patient
treated with onartuzumab had a CR.
Biomarkers
MET IHC was performed centrally and comprised both
staining intensity and percentage of MET-expressing tumor cells
(Appendix Fig A1, online only). By IHC, MET-positive tumors
were deﬁned as those with 50% or more of tumor cells showing
moderate and/or strong staining intensity (MET 2+ or 3+). Overall
agreement between central laboratory pathologists was greater
than 88% (Appendix Table A1, online only).
A greater proportion of patients with MET IHC 2+ status were
FISH negative (85.1%) than FISH positive (65.4%), whereas more
patients with MET IHC 3+ status were FISH positive (34.6%) than
FISH negative (14.9%). The PFS HR in patients with MET IHC 3+
status (n = 54) was 0.86 (95% CI, 0.58 to 1.29) compared with 1.06
(95% CI, 0.85 to 1.32) in patients (n = 195) with MET IHC 2+ status
(Fig 3B). There were no statistically signiﬁcant differences in OS, PFS,
or ORR between the onartuzumab and placebo arms when analyzed
by MET FISH status. The OS HR in patients with FISH-negative
disease was 1.36 (95% CI, 0.98 to 1.89) compared with 1.28 (95% CI,
0.82 to 2.01) in patients with FISH-positive disease. The PFS HR in
the FISH-negative group was 1.02 (95% CI, 0.80 to 1.30) compared
1.0
0.8
0.6
0.4
0.2
Placebo + erlotinib
Onartuzumab + erlotinib
249
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  1
  2
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EGFR  mutation
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  No
249
37
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218
31
157
92
195
54
150
85
29
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2.6
2.7
2.0
3.7
1.9
3.8
2.7
1.5
2.7
1.4
2.7
1.5
8.5
1.5
Median
(months)
Onartuzumab + Erlotinib
(n = 250)
No.
250
35
182
33
210
40
161
89
198
52
165
71
28
222
2.7
3.0
2.7
2.4
2.7
2.7
2.9
2.0
2.7
2.5
2.7
2.7
NE
2.6
1.01
0.79
1.04
1.02
0.98
1.19
0.94
1.17
1.06
0.86
1.02
1.07
1.15
0.97
0.83 to 1.22
0.45 to 1.39
0.83 to 1.30
0.60 to 1.73
0.80 to 1.21
0.71 to 1.99
0.73 to 1.20
0.85 to 1.59
0.85 to 1.32
0.58 to 1.29
0.80 to 1.30
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0.48 to 2.76
0.80 to 1.19
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B
Fig 3. (A) Kaplan-Meier curves of progression-free survival (PFS) in the intent-to-treat population. Crosses indicate censored patients. (B) Subanalysis of PFS in key clinical
subgroups. FISH, ﬂuorescence in situ hybridization; HR, hazard ratio; IHC, immunohistochemistry.
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with 1.07 (95%CI, 0.75 to 1.51) for the FISH-positive group (Fig 3B).
Patients with FISH-negative disease had an ORR of 9.7% and 8.7%
and patients with FISH-positive disease had an ORR of 11.8% and
4.2% in the onartuzumab and placebo arms, respectively.
Although there was no signiﬁcant association between EGFR
mutation status and treatment outcomes, there was a trend toward
shorter OS in patients with activating mutations who received
onartuzumab and erlotinib, albeit with a small number of events in
each arm (two for placebo and seven for onartuzumab; HR, 4.68;
95% CI, 0.97 to 22.63; Figs 2B and 3B). Similarly, there was no
signiﬁcant difference observed in OS or PFS between treatments in
patients with ampliﬁcation of MET (OS: HR, 1.66; 95% CI, 0.86 to
3.21; PFS: HR, 1.47; 95% CI, 0.86 to 2.51) or EGFR ampliﬁcation
(OS: HR, 2.01; 95% CI, 0.83 to 4.87; PFS: HR, 1.46; 95% CI, 0.7 to
3.03). On the basis of an unstratiﬁed analysis of the biomarker
subgroups, there was no signiﬁcant difference in PFS or OS for any
other subgroup; however, patients who had a KRAS mutation
showed a borderline association of beneﬁt in the onartuzumab arm
(PFS: HR, 0.67; 95% CI, 0.43 to 1.05; OS: HR, 0.95; 95% CI, 0.52 to
1.74; Figs 4A and 4B).
Safety
Median dose intensity of both onartuzumab and placebo was
100%. The median duration of treatment was longer for patients
who received onartuzumab plus erlotinib (60.9 days [four doses])
than for those who received placebo plus erlotinib (40.6 days [2.5
doses]). Erlotinib was administered for a median of 66.5 days (63
doses) to patients in the onartuzumab arm and 49 days (47.5 doses)
in the placebo arm.
Amajority of patients reported at least one AE,mostly grade 1 or
2 in severity. There was a similar number in each arm: 245 (98.8%) in
the onartuzumab arm and 234 (95.9%) in the placebo arm. Themost
common AEs (all grades) in the onartuzumab arm were rash (39%),
diarrhea (39%), and dermatitis acneiform (32%). In the placebo arm,
the most common AEs (all grades) were diarrhea (47%), rash (37%),
decreased appetite (32%), and fatigue (30%; Table 2). AEs occurring
in at least 5% more patients in the onartuzumab arm than in the
placebo arm were peripheral edema (22% v 8%, respectively),
hypoalbuminemia (17% v 4%, respectively), and dermatitis acnei-
form (32% v 26%, respectively; Table 2). Grade 3 to 5 AEs were
reported in 139 patients (56.0%) in the onartuzumab arm and 125
(51.2%) in the placebo arm. Grade 5 AEs occurred in 6.9% and 4.1%
of patients in the onartuzumab and placebo arms, respectively. Se-
rious AEs (SAEs) were reported in 84 patients (33.9%) in the
onartuzumab arm and 75 (30.7%) in the placebo arm. Most SAEs
were grade 3 in severity, with similar rates between arms. Grade 4 and
5 SAEsweremore frequent in the onartuzumab arm (5.2%and 6.9%,
respectively) than in the placebo arm (2.9% and 4.1%, respectively).
The most frequently reported SAEs were respiratory, thoracic, and
mediastinal disorders. The rate of AEs leading to onartuzumab or
placebo discontinuationwas 7.7% in the onartuzumab arm and 4.5%
in the placebo arm.
DISCUSSION
The phase IIIMETLung trial did notmeet its primary end point, and
the results did not conﬁrm the ﬁndings of the earlier phase II study.
Multiple exploratory biomarkers were also assessed, and these results
were consistently negative across all biomarker subgroups.
The combination of onartuzumab and erlotinib demonstrated
a tolerable safety proﬁle, supporting the ﬁndings of the phase II
study.17 The peripheral edema and hypoalbuminemia observed
were likely to be a class effect of MET inhibition, because these AEs
were also observed in the phase II study,17 the onartuzumab
program as a whole,21 and a study of rilotumumab, another in-
hibitor of MET signaling.22
The results are in stark contrast to those of the phase II
study,17 and a large number of comparisons have been per-
formed between the studies in an effort to identify variables that
might account for the different outcomes. With respect to pa-
tient selection, MET IHC for the phase II study was performed at
Genentech (San Francisco, CA).5 The cutoff for MET positivity
was deﬁned before unblinding of the phase II trial. The pa-
thologist who developed the assay at Genentech worked closely
with Ventana to ensure consistency in how the assay was per-
formed in the phase II study. The pathologist directly trained the
central laboratories that performed the IHC for the phase III
trial. Additionally, a three-way concordance analysis was per-
formed before unblinding of the phase III trial to ensure con-
sistency in assay and pathologist performance. All clinical and
demographic variables were similar between the phase II and III
studies. Taken together, it is unlikely that patient selection had an
impact on the outcome of the phase III study. However, this
study was based on IHC analysis, and emerging data suggest that
splice-site mutations, which are drivers of MET activity, may be
a better way to select patients for MET small-molecule in-
hibitors.23-25 In this context, it is important to note that it is
presently unclear whether onartuzumab or rilotumumab would
be efﬁcacious in patients whose tumors harbor splice-site mu-
tations, and none of the onartuzumab studies were designed to
evaluate this question.
In the phase II trial, both PFS and OS favored the combination
treatment, whereas the opposite was true in the phase III trial.
Thus, it is unclear how the prioritization of end points would have
affected the outcome.
As for the size of the phase II versus III study, statistical
modeling showed that the phase II results were robust. A larger
phase II study would have been required (assuming that the phase
III results revealed the risk–beneﬁt ratio of onartuzumab accu-
rately) to mitigate the treatment effect observed in the phase II.
Additionally, patients with EGFR mutation–positive disease,
included in this study, showed a detrimental trend when treated
with a combination of onartuzumab and erlotinib. Although the
number of patients for this analysis was limited, this result
suggests that this population of patients does not beneﬁt from the
addition of onartuzumab to erlotinib, despite compelling pre-
clinical data to the contrary. The treatment of EGFR wild-type
NSCLC has changed, with studies comparing EGFR TKIs and
chemotherapy in a second-line setting showing that chemo-
therapy may be better than erlotinib, in the absence of a con-
ﬁrmed mutation.26,27
Results from other phase III studies using different inhibitors
of MET signaling have also been negative. A phase II trial of the
HGF inhibitor rilotumumab in gastric cancer demonstrated posi-
tive results.28 However, similarly to METLung, the RILOMET-1
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Baseline Risk Factors
Total
No.
Median
(months)
Placebo + Erlotinib
(n = 249)
1/100
Favors
onartuzumab +
erlotinib
Favors
placebo +
erlotinib
1 100
EventsNo.
All patients
BRAF mutation
Detected
Not detected
EGFR mutation
Detected
No call
Not detected
KRAS mutation
Detected
No call
Not detected
PIK3CA mutation
Detected
No call
Not detected
MET gene amplification
Amplified
Other
EGFR gene amplification
Amplified
Other
MET FISH
Positive
Negative
EGFR FISH
Positive
Negative
499
5
311
20
50
246
88
15
213
15
36
265
65
91
41
242
156
315
280
191
249
3
149
12
20
120
42
7
103
7
17
128
39
46
23
116
85
150
137
98
204
3
120
3
16
104
38
6
79
4
13
106
36
36
20
90
72
118
109
81
2.6
1.3
2.0
NE
2.7
1.4
1.4
1.9
2.8
4.1
3.7
1.4
1.4
2.8
2.8
2.7
1.5
2.7
2.7
2.2
Median
(months)
Onartuzumab + Erlotinib
(n = 250)
EventsNo.
250
2
162
8
30
126
46
8
110
8
19
137
26
45
18
126
71
165
143
93
210
2
137
3
25
111
41
8
90
7
16
116
23
35
14
103
58
141
116
83
2.7
2.4
2.7
NE
1.7
2.7
3.1
1.3
2.7
3.4
1.6
2.7
1.3
2.8
1.6
2.8
2.7
2.7
2.8
2.6
1.01
1.73
1.04
1.57
1.25
0.94
0.67
2.58
1.13
1.88
1.75
0.96
1.47
0.94
1.46
1.01
1.07
1.02
1.02
1.04
0.83 to 1.22
0.23 to 12.78
0.81 to 1.33
0.31 to 7.90
0.66 to 2.38
0.72 to 1.23
0.43 to 1.05
0.82 to 8.08
0.83 to 1.52
0.55 to 6.45
0.81 to 3.79
0.73 to 1.24
0.86 to 2.51
0.59 to 1.49
0.70 to 3.03
0.76 to 1.35
0.75 to 1.51
0.80 to 1.30
0.79 to 1.33
0.77 to 1.42
95% CIHR
A
1/100
Favors
onartuzumab +
erlotinib
Favors
placebo +
erlotinib
1 100
Baseline Risk Factors
Total
No.
Median
(months)
Placebo + Erlotinib
(n = 249)
EventsNo.
Median
(months)
Onartuzumab + Erlotinib
(n = 250)
EventsNo. 95% CIHR
All patients
BRAF mutation
Detected
Not detected
EGFR mutation
Detected
No call
Not detected
KRAS mutation
Detected
No call
Not detected
PIK3CA mutation
Detected
No call
Not detected
MET gene amplification
Amplified
Other
EGFR gene amplification
Amplified
Other
MET FISH
Positive
Negative
EGFR FISH
Positive
Negative
499
5
331
20
50
246
88
15
213
15
36
265
65
91
41
242
156
315
280
191
249
3
149
12
20
120
42
7
103
7
17
128
39
46
23
116
85
150
137
98
114
1
68
1
10
58
19
4
46
1
7
61
24
21
11
50
45
62
61
46
9.1
NE
9.1
NE
6.5
7.8
NE
5.1
9.1
NE
7.4
9.1
9.6
9.4
10.1
9.4
9.4
9.9
9.8
7.8
250
2
162
8
30
126
46
8
110
8
19
137
26
45
18
126
71
165
143
93
130
1
92
2
18
73
26
6
61
4
12
77
16
20
10
65
36
87
74
49
6.8
NE
6.5
12.6
5.6
6.4
8.8
4.6
6.3
5.0
3.3
6.5
6.0
8.4
6.0
7.1
6.4
6.9
7.0
6.8
1.27
> 999.99
1.39
2.92
1.42
1.34
0.95
2.08
1.63
3.73
2.25
1.33
1.66
1.13
2.01
1.35
1.28
1.36
1.42
1.13
0.98 to 1.63
0.0 to NE
1.01 to 1.90
0.26 to 32.93
0.64 to 3.19
0.95 to 1.89
0.52 to 1.74
0.51 to 8.49
1.11 to 2.39
0.39 to 36.02
0.84 to 6.03
0.95 to 1.86
0.86 to 3.21
0.60 to 2.11
0.83 to 4.87
0.93 to 1.96
0.82 to 2.01
0.98 to 1.89
1.01 to 1.99
0.76 to 1.70
B
Fig 4. Subanalyses of (A) progression-free and (B) overall survival in biomarker subgroups. EGFR, epidermal growth factor receptor; FISH, ﬂuorescence in situ
hybridization; HR, hazard ratio; NE, not evaluable.
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(Rilotumumab With ECX As First-Line Therapy in Advanced MET-
Positive Gastric or Gastroesophageal Junction Adenocarcinoma)
phase III trial in gastric cancer failed tomeet its primary end point; the
median OS of 9.6 months with rilotumumab was signiﬁcantly
lower than 11.5 months in the placebo arm (stratiﬁed HR, 1.37;
95% CI, 1.06 to 1.78; log-rank P = .016). Additionally, the
12-month survival rate (38.4% v 49.7%) and ORR (30% v 39.2%)
were lower in the rilotumumab arm than in the placebo arm. This
trial was closed prematurely because of lack of activity and
the observation of an imbalance of deaths between the two arms
(128 v 107).22
The collective experience with onartuzumab plus standard of
care in multiple phase II and III trials of gastroesophageal
adenocarcinoma,29 triple-negative breast cancer,30 recurrent
glioblastoma,31 and colorectal carcinoma32 has also included
disappointing efﬁcacy results. These ﬁndings, together with the
results from the METLung trial, suggest that MET inhibition via
ligand-blocking antibodies may not be an effective therapeutic
strategy.
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Appendix
Table A1. Central Laboratory Pathologist Percentage Agreement
Agreement Rate No. (%)
Laboratory one
Overall percentage agreement 191 of 207 (92.3)
Average positive agreement 88 of 103 (85.4)
Average negative agreement 103 of 104 (99.0)
Laboratory two
Overall percentage agreement 135 of 153 (88.2)
Average positive agreement 57 of 75 (76.0)
Average negative agreement 78 of 78 (100.0)
Clinical
Diagnosis
Negative
Negative
Positive
Positive
No or equivocal staining in tumor
cells or < 50% tumor cells with
membrane and/or cytoplasmic
staining
≥ 50% tumor cells with weak or
higher membrane and/or
cytoplasmic staining but < 50%
tumor cells with moderate or higher
staining intensity
≥ 50% tumor cells with moderate
or higher membrane and/or
cytoplasmic staining but < 50%
tumor cells with strong staining
intensity 
≥ 50% tumor cells with strong or
higher membrane and/or
cytoplasmic staining intensity
Representative
IHC Images
IHC
Score
0
1+
2+
3+
Staining Criteria
Fig A1. MET immunohistochemistry (IHC) scoring criteria.
© 2016 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Spigel et al
Downloaded from ascopubs.org by Queensland University of Technology on January 29, 2017 from 131.181.004.100
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
